- New addition to LISA TRACKER, the market’s most complete range of
biotherapy monitoring kits
- New test in the field of auto-immune and inflammatory
diseases
Croissy-Beaubourg and Montpellier, March 25, 2015 – Theradiag (ISIN:
FR0004197747, Ticker: ALTER), a company specializing in theranostics and in
vitro diagnostics, announced today that it has obtained CE marking for its
monitoring test of Stelara® (ustekinumab), the 10th biotherapy
monitoring test of Theradiag’s LISA TRACKER range.
Stelara® is fully human monoclonal antibody that targets the cytokines
(interleukin) IL-12 and IL-23 proteins. It was approved for use in moderate to
severe plaque psoriasis and psoriatic arthritis. Psoriasis is a very common
autoimmune disease, affecting two-to-three percent of the world’s population[1].
Ustekinumab is also currently undergoing clinical trial[2]
for the treatment of Crohn’s Disease. Sales of Stelara® were $1.3 billion in
2014.
“Theradiag is the only company in the world to offer such a large range of
monitoring tests for the treatment of autoimmune and inflammatory diseases. To
maintain our leadership on the market, we will develop monitoring kits for all
available and future biotherapies in the fields of autoimmune diseases and
cancer. The CE marking that we announce today, the 10th in our LISA
TRACKER range, is a proof of this commitment” concludes Michel Finance,
Chief Executive Officer of Theradiag.
To read more information please click on this link to view the full THERADIAG receives CE marking for its 10th biotherapy monitoring test
[2]Janssen
Biotech (Johnson & Johnson) is currently conducting a Phase III study of
ustekinumab in Crohn’s disease